CTOs on the Move

Y's Therapeutics

www.ysthera.com

 
Y's Therapeutics, Inc is a San Bruno, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ysthera.com
  • 1111 Bayhill Dr
    San Bruno, CA USA 94066
  • Phone: 650.777.7000

Executives

Name Title Contact Details

Similar Companies

InnerScope Hearing Technologies

Homepage for InnerScope Hearing Technologies, a hearing care company who sells Direct-to-Consumer Hearing Aids.

Pfeiffer Pharmaceuticals

Pfeiffer Pharmaceuticals is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Apexigen, Inc

Apexigen, Inc. is a privately held biopharmaceutical company discovering and developing innovative antibody therapeutics for the treatment of life-threatening and difficult-to-treat diseases. Using its proprietary antibody technology platform, Apexigen has discovered a pipeline of product candidates, which are currently at varying stages of development. The lead product candidate, APX005M, is a novel immuno-oncology antibody that stimulates and enhances an immune response against cancer. Apexigen is developing other product candidates in partnership with four leading biopharmaceutical companies in China. In addition, Apexigen has formed strategic partnerships with multi-national pharmaceutical companies, including Janssen Biotech, Alcon Laboratories and Toray Industries to discover first-in-class antibody lead candidates for the partners' programs.

United Vein Centers

United Vein Centers is Tampas choice for vein care. We have extensive experience treating both varicose & spider veins - particularly our physician, Dr. Wazni.

Precision Medicine Group

We founded Precision Medicine Group in 2012 because we believed there was a transformational opportunity to improve the process of bringing new drugs to market. It involves utilizing technology, data, and human expertise. It is a big challenge that requires diverse talents. Our model involves both nurturing and investing organically and acquiring capabilities that we do not have but critically need. Our core executive team is anchored to this model, building life science services that address fundamental changes in healthcare that are necessary for health and outcomes improvement.